HALF-YEARLY REPORT ON THE LIQUIDITY CONTRACT WITH GILBERT DUPONT Paris, France, January 2, 2017

Pursuant to the liquidity contract entrusted to Gilbert Dupont, on 31 December 2016 the following assets appeared on the liquidity account:

  • Number of shares: 23,681

  • Cash balance of the liquidity account: €94,289.08

    As a reminder, at the time of the last Half-Yearly report on 30 June 2016, the following resources were booked to the liquidity account:

  • Number of shares: 30,282

  • Cash balance of the liquidity account: €81,237.08

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com

M auna Kea Technolog ies

Benoit Jacheet CFO

investo rs@maunakeatech.co m

United States

Zack Kubow / Lee Roth The Ruth Group

646-536-7020 / 7012

z kubo w @theruth gro up.co m

lro th@ther uth gro up.co m

U.S. M edia Christopher Hippolyte The Ruth Group

646-536-7023

chippo ly te@th erut hgro up. co m

France and E urope

NewCap - Investor Relations Florent Alba

+33 (0)1 44 71 94 94

maunakea@newcap.fr

1

Mauna Kea Technologies SA published this content on 02 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 03 January 2017 09:07:07 UTC.

Original documenthttp://www.maunakeatech.com/sites/default/files/press_relase/upload/mauna_kea_technologies_final_pr_hy_report_on_liquidity_contract_20170102.pdf

Public permalinkhttp://www.publicnow.com/view/1FFB2FA8BDA8A856A4BB2388B99BAA22E1037BB4